Quantcast

Accuracy In Lung Cancer Diagnosis

October 1, 2010

(Ivanhoe Newswire) ““ MircoRNA’s are making the diagnosis and treatment of lung cancer faster and more precise.

Lung cancers are traditionally divided into two main groups, either neuroendocrine or non-small cell lung cancer.  In 20 to 30 percent of the cases, making a definitive diagnosis of the tumor subtype using fine needle biopsy can be quite difficult.  Rosetta Genomics test, which is based on a panel of MicroRNAs, is going to make that 20 to 30 percent less difficult . . . and more definite.

“Subclassification has become very important in the determination of patient management,” which Tina B. Edmonston, M.D., director of the clinical laboratory at Rosetta Genomics, Ltd., was quoted as saying.  “This subclassification leads to treatment decisions, so it is very important to make the diagnosis accurately.”

Edmonston and colleagues, using their propriety assay, were able to further subclassify non-small cell lung cancer into squamous and non-squamous, and neuroendocrine into small cell lung cancer and carcinoid with a high level of sensitivity and specificity.

The researchers concluded that this assay would result in better decisions because not all subtypes of lung cancer will respond to definite drugs and some may even pose unique risks.

SOURCE: Oncology, September 2010




comments powered by Disqus